Back
Perspective Therapeutics Quote, Financials, Valuation and Earnings
Invest. Do Good. Get Rewarded. Just $0.25/Share!
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
30
CATX
Perspective Therapeutics
Last Price:
3.05
Seasonality Move:
34.33%
7 Day Trial
ALL ACCESS PASS
$
7
Start Investing Smarter Unlock Louis Navellier's Stock Grader for free
Louis' clients have paid up to $30,000 for these insights - now you can try it at no cost.Perspective Therapeutics Price Quote
$3.05
-3.12 (-50.57%)
(Updated: November 21, 2024 at 3:10 PM ET)
Perspective Therapeutics Key Stats
Sell
30
Perspective Therapeutics (CATX)
is a Sell
Day range:
$6.01 - $6.87
52-week range:
$2.28 - $19.05
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
37.58
P/B ratio:
1.43%
Volume:
1.2M
Avg. volume:
972.7K
1-year change:
149.6%
Market cap:
$470.4M
Revenue:
$0
EPS:
$-1.46
How Much Does Perspective Therapeutics Make?
Data Unavailable
Is Perspective Therapeutics Growing As A Company?
Data Unavailable
Perspective Therapeutics Stock Price Performance
-
Did Perspective Therapeutics Stock Go Up Last Month?
Perspective Therapeutics share price went down by -51.23% last month -
Did CATX's Share Price Rise Over The Last Year?
CATX share price rose by 149.6% over the past 1 year
What Is Perspective Therapeutics 52-Week High & Low?
-
What Is Perspective Therapeutics’s 52-Week High Share Price?
Perspective Therapeutics has traded as high as $19.05 over the past 52 weeks -
What Is Perspective Therapeutics’s 52-Week Low Share Price?
Perspective Therapeutics has traded as low as $2.28 over the past 52 weeks
Perspective Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Perspective Therapeutics?
-
How Much Debt Does Perspective Therapeutics Have?
Total long term debt quarterly is $0 -
How Much Cash Does Perspective Therapeutics Have?
Cash and short term investments quarterly total is $267.8M -
What Is Perspective Therapeutics’s Book Value Per Share?
Book value per share is 4.86
Is Perspective Therapeutics Cash Flow Positive?
-
What Is CATX Cash Flow From Operations?
Cash flow from operations (TTM) is -$696K -
What Is Perspective Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $289.4M -
What Is Perspective Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$80.4M
Perspective Therapeutics Return On Invested Capital
Data Unavailable
Perspective Therapeutics Earnings Date & Stock Price
-
What Is Perspective Therapeutics's Stock Price Today?
A single share of CATX can be purchased today for 6.17 -
What Is Perspective Therapeutics’s Stock Symbol?
Perspective Therapeutics trades on the nyam under the ticker symbol: CATX -
When Is Perspective Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Perspective Therapeutics is scheduled on March 28, 2025 -
When Is CATX's next ex-dividend date?
Perspective Therapeutics's next ex-dividend date is November 21, 2024 -
How To Buy Perspective Therapeutics Stock?
You can buy Perspective Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Perspective Therapeutics Competitors
-
Who Are Perspective Therapeutics's Competitors?
Below is a list of companies who compete with Perspective Therapeutics or are related in some way:
Perspective Therapeutics Dividend Yield
-
What Is CATX Dividend Yield?
Perspective Therapeutics’s dividend yield currently is 0% -
What Is Perspective Therapeutics’s Payout Ratio?
Perspective Therapeutics’s payout ratio is 0% -
When Did Perspective Therapeutics Last Pay A Dividend?
The latest dividend pay date is November 21, 2024 -
What Is Perspective Therapeutics’s Dividend Per Share?
Perspective Therapeutics pays a dividend of $0.00 per share
Perspective Therapeutics Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | -3.06% |
| Revenue: | 0% | 55.1% |
Analyst Recommendations
| Buy Recommendations: | 9 |
|---|---|
| Hold Recommendations: | 0 |
| Sell Recommendations: | 0 |
| Price Target: | 21.35 |
| Upside from Last Price: | 246.03% |